| Literature DB >> 35615732 |
Qiuyan Li1, ZeSong Yang1, Shiwen Zheng2, Yangbiao Wu1, Wanghai Cai1, Minxiong Hu1, Qingguo Zhu1, Liefu Ye1.
Abstract
To compare the applicability of 14 equations of estimating glomerular filtration rate (eGFR) before and after nephron-sparing surgery (NSS) for renal function assessment of patients with renal tumors. Preoperative and postoperative GFR is measured by emission computed tomography (ECT) with 99mTc-DTPA as an imaging agent as reference GFR (rGFR) to compare with all formulas. Spearman correlation analysis and Bland-Altman agreement analysis were used to evaluate the correlation between rGFR and eGFR1 to 14 before and after surgery. A total of 50 cases including 22 males and 28 females were included. The results of preoperative eGFR1-14 correlated with rGFR (P < 0.05). The calculation results of all estimation formulas have a significant correlation with preoperative GFR. Preoperative MDRD-I, CKD-EPI SCysC, and FAS Scr-SCysC have good consistency. The CG formula has the highest precision and FAS Scr-SCysC has the highest accuracy. A total of 30 patients followed up after surgery, and postoperative rGFR correlated with CG, CKD-EPI, FAS, and BIS formulas (P < 0.05). But postoperative rGFR has no significant correlation with MDRD and Schwartz (P > 0.05). Postoperative CKD-EPI Scr-SCysC has best consistency, and FAS Scr-SCysC has the highest accuracy and precision. Our data suggest that eGFR equations evaluated by both serum creatinine (Scr) and cystatin C (SCysC) is not necessarily better than those evaluated by one of them alone. Among all enrolled equations, FAS Scr-SCysC is the best one to evaluate postoperative GFR in patients with renal tumors.Entities:
Mesh:
Year: 2022 PMID: 35615732 PMCID: PMC9110198 DOI: 10.1155/2022/3330442
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Basic characteristics of the 50 patients.
| Characteristic ( | Male | Female |
|---|---|---|
|
| 22 | 28 |
| Age (years) | 17–80 | 29–73 |
| Average age (years) | 53.8 ± 10.2 | 50.0 ± 10.5 |
| Height (cm) | 171.6 ± 6.1 | 159.0 ± 4.1 |
| Weight (kg) | 70.4 ± 9.2 | 57.4 ± 6.6 |
| Plasma creatinine (mg/dl) | 0.94 ± 0.086 | 0.75 ± 0.089 |
| Plasma urea nitrogen (mg/dl) | 98.9 ± 21.5 | 91.1 ± 18.5 |
| Plasma albumin (g/dl) | 440.0 ± 20.0 | 433.2 ± 26.3 |
| rGFR (ml/min/1.73 m−2) | 90.04 ± 15.42 | 91.72 ± 19.67 |
| Tumor size (cm) | 3.3 (1.3–10.5) | 4.1 (0.8–8.0) |
|
| ||
| rGFR category | ||
| rGFR ≥ 90 | 10 | 14 |
| 60 ≤ rGFR < 90 | 12 | 11 |
| rGFR < 60 | — | 3 |
|
| ||
| Pathologic type | ||
| Angiomyolipoma (AML) | 3 | 11 |
| chRCC | 2 | — |
| ccRCC | 16 | 13 |
| Mucinous tubular and spindle cell carcinoma | — | 1 |
| ESC RCC | 1 | — |
| RNET | — | 1 |
| Others | — | 2 |
RGFR, reference glomerular filtration rate; tumor size, the maximum diameter of the tumor; AML, angiomyolipoma; chRCC, chromophobe renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; ESC RCC, eosinophilic solid and cystic renal cell carcinoma; RNET, renal neuroendocrine tumor.
14 formulas for calculating the glomerular filtration rate.
| eGFR1 | CG formula [ |
|
| |
| eGFR2 | MDRD (simplified) I [ |
| eGFR3 | MDRD (simplified) II [ |
| eGFR4 | MDRD-C (for Chinese) [ |
| eGFR5 | MDRD formula [ |
| eGFR6 | CKD-EPI Scr [ |
|
| |
|
| |
|
| |
| eGFR7 | CKD-EPISCysC [ |
| eGFR8 | CKD-EPIScr-SCysC [ |
|
| |
|
| |
|
| |
|
| |
| eGFR9 | SchwartzScr-SCysC [ |
| eGFR10 | FASScr [ |
| 0.988 (age−40) × 107.3/(Scr/QScr) when age > 40 | |
| QScr = 0.7 mg/dL (if female); QScr = 0.9 mg/dL (if male) | |
| eGFR11 | FASSCysC [ |
| 0.988 (age−40) × 107.3/(SCysC/QSCysC) when age>40 | |
|
| |
| eGFR12 | FASScr-SCysC [ |
|
| |
| eGFR13 | BIS − 1 Scr [ |
| eGFR14 | BIS − 2 Scr-SCysC [ |
Spearman correlation analysis of 14 evaluation formulas for preoperative GFR.
| Formulas | eGFR (ml/min/1.73 m−2) | Spearman's correlation | |
|---|---|---|---|
|
|
| ||
| rGFR | 90.98 ± 22.90 | — | — |
| eGFR1 | 86.61 ± 22.03 | 0.564 | 0.000 |
| eGFR2 | 91.11 ± 15.42 | 0.413 | 0.003 |
| eGFR3 | 85.72 ± 14.51 | 0.413 | 0.003 |
| eGFR4 | 112.34 ± 19.01 | 0.413 | 0.003 |
| eGFR5 | 97.64 ± 15.97 | 0.421 | 0.002 |
| eGFR6 | 92.96 ± 15.49 | 0.524 | 0.000 |
| eGFR7 | 102.19 ± 24.00 | 0.541 | 0.000 |
| eGFR8 | 99.05 ± 10.05 | 0.561 | 0.000 |
| eGFR9 | 102.54 ± 15.60 | 0.455 | 0.001 |
| eGFR10 | 89.18 ± 17.41 | 0.547 | 0.000 |
| eGFR11 | 104.05 ± 34.59 | 0.555 | 0.000 |
| eGFR12 | 94.69 ± 22.64 | 0.590 | 0.000 |
| eGFR13 | 102.83 ± 38.33 | 0.548 | 0.000 |
| eGFR14 | 101.68 ± 31.10 | 0.586 | 0.000 |
Comparison of the correlation between eGFR and rGFR of each formula, P < 0.05.
Figure 1Bland–Altman plot of preoperative eGFR and rGFR in 50 patients.
Spearman correlation analysis and Bland–Altman agreement analysis of 14 eGFR and rGFR after surgery.
| Formula | eGFR | Spearman's correlation | Arithmetic mean | Slope | Intercept | 95% CI ( | |
|---|---|---|---|---|---|---|---|
| R |
| ||||||
| rGFR | 93.67 ± 22.08 | — | — | — | — | — | — |
| eGFR1 | 87.92 ± 23.51 | 0.499 | 0.005 | −5.7262 | 0.08306 | −13.2684 | 29/30 |
| eGFR2 | 89.97 ± 18.30 | 0.305 |
| −3.7002 | −0.2787 | 21.8890 | 29/30 |
| eGFR3 | 84.65 ± 17.22 | 0.305 |
| −9.0210 | −0.3672 | 23.7211 | 29/30 |
| eGFR4 | 110.93 ± 22.57 | 0.305 |
| 17.2630 | 0.03263 | 13.9253 | 28/30 |
| eGFR5 | 94.77 ± 19.47 | 0.324 |
| 1.0985 | −0.1824 | 18.2889 | 29/30 |
| eGFR6 | 91.49 ± 17.38 | 0.421 | 0.021 | −2.1787 | −0.3217 | 27.6003 | 29/30 |
| eGFR7 | 95.27 ± 23.23 | 0.444 | 0.014 | 1.6039 | 0.06294 | −4.3426 | 29/30 |
| eGFR8 | 94.02 ± 19.33 | 0.471 | 0.009 | 0.3488 | −0.1644 | 15.7741 | 30/30 |
| eGFR9 | 97.34 ± 14.49 | 0.284 |
| 3.6656 | −0.5510 | 56.2854 | 29/30 |
| eGFR10 | 88.86 ± 21.03 | 0.480 | 0.007 | −4.8075 | −0.06502 | 1.1269 | 28/30 |
| eGFR11 | 95.11 ± 27.50 | 0.511 | 0.004 | 1.4373 | 0.2681 | −23.8695 | 29/30 |
| eGFR12 | 90.69 ± 21.65 | 0.537 | 0.002 | −2.9858 | −0.02436 | −0.7408 | 29/30 |
| eGFR13 | 100.77 ± 34.90 | 0.581 | 0.001 | 7.0974 | 0.5963 | −50.8760 | 29/30 |
| eGFR14 | 94.74 ± 24.52 | 0.582 | 0.001 | 1.0664 | 0.1288 | −11.0627 | 29/30 |
P > 0.05, no significant correlation;95% CI, numbers within 95% CI.